Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.57 |
| ▸ | PDE10A | Q9Y233 | 16/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | SORD | Q00796 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15537495 | 0.98 | TRPV3 (0.58) | TRPV3PDE10AHRH3 | |
| SCHEMBL25189276 | 0.84 | HTR3E (0.58) | TRPV3PDE10AHRH3 | |
| SCHEMBL6475308 | 0.84 | GAA (0.51) | TRPV3PDE10AHRH3 | |
| SCHEMBL20436562 | 0.82 | HRH3 (0.54) | TRPV3PDE10AHRH3 | |
| SCHEMBL2456126 | 0.81 | PDE10A (0.55) | TRPV3PDE10A | |
| SCHEMBL14818715 | 0.81 | PDE10A (0.59) | TRPV3PDE10A | |
| SCHEMBL29228864 | 0.81 | PDE10A (0.55) | TRPV3PDE10A | |
| SCHEMBL8084822 | 0.81 | PDE10A (0.55) | TRPV3PDE10A | |
| SCHEMBL14857760 | 0.81 | PDE10A (0.55) | TRPV3PDE10A | |
| SCHEMBL29801256 | 0.81 | PDE10A (0.55) | TRPV3PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409542-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2024-12-12 | — | — | US | disclosed |
| EP-4408845-A1 | NOVEL COMPOUNDS | Sitryx Therapeutics Limited (GB) | 2024-08-07 | — | — | EP | disclosed |
| CN-118139864-A | New compounds | 西特瑞治疗有限公司 | 2024-06-04 | — | — | CN | disclosed |
| WO-2023052783-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-04-06 | — | — | WO | disclosed |
| EP-2854804-B1 | PYRROLIDINO HETEROCYCLES | HOFFMANN LA ROCHE (CH) | 2019-11-20 | — | — | EP | disclosed |
| US-20190201404-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2019-07-04 | — | — | US | disclosed |
| US-10278972-B2 | Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2019-05-07 | — | — | US | disclosed |
| US-20170216293-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2017-08-03 | — | — | US | disclosed |
| US-9670227-B2 | Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2017-06-06 | — | — | US | disclosed |
| US-9540384-B2 | Pyrrolidino heterocycles | HOFFMANN-LA ROCHE, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| EP-2886545-B1 | New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2016-06-29 | — | — | EP | disclosed |
| WO-2015097123-A1 | NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2015-07-02 | — | — | WO | disclosed |
| US-20150175623-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2015-06-25 | — | — | US | disclosed |
| EP-2886545-A1 | New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2015-06-24 | — | — | EP | disclosed |
| CN-104725397-A | Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them | SERVIER LAB | 2015-06-24 | — | — | CN | disclosed |
| EP-2854804-A1 | PYRROLIDINO HETEROCYCLES | F. Hoffmann-La Roche AG (CH) | 2015-04-08 | — | — | EP | disclosed |
| US-20150087644-A1 | PYRROLIDINO HETEROCYCLES | HOFFMANN-LA ROCHE INC. (US) | 2015-03-26 | — | — | US | disclosed |
| WO-2013178569-A1 | PYRROLIDINO HETEROCYCLES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216293-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TYMS, TYMP, TPX2 | TRPV3 4663/4885PDE10A 1854/4885HRH3 727/4885 |
| US-10278972-B2 | Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them | TYMS, TYMP, TPX2 | TRPV3 4663/4885PDE10A 1854/4885HRH3 727/4885 |
| US-20150087644-A1 | PYRROLIDINO HETEROCYCLES | PDE3A, PDE3B, PDE2A | TRPV3 1399/4885PDE10A 5/4885HRH3 1713/4885 |
| US-20190201404-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TYMS, TYMP, TPX2 | TRPV3 4663/4885PDE10A 1854/4885HRH3 727/4885 |
| US-20150175623-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TYMS, TYMP, TPX2 | TRPV3 4663/4885PDE10A 1854/4885HRH3 727/4885 |
| US-20240409542-A1 | NOVEL COMPOUNDS | CD47, GPR119, LRBA | TRPV3 4499/4885PDE10A 2788/4885HRH3 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.